Company / Cost of Revenue
Ligand Pharmaceuticals, Inc. Cost of Revenue History
FY2016-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.3M
FY2018
5-year range
-
FY2016-FY2018
Trend
+18.1%
vs FY2017
Sector context
#74 of 85
Health Care
What the data says
Ligand Pharmaceuticals, Inc.'s cost of revenue of $6M is lower than 87% of companies in the Health Care sector (FY2018). Increased from $6M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2018.
Increased from $6M to $6M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 85This company $6.3M Sector average $2.0B
▼
-99.7% below sector average
Key checks
Key Insights
- In FY2018, cost of revenue increased 18.1% year-over-year.
- Ranks #74 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $6.3M | +18.1% |
| FY2017 | $5.4M | -3.7% |
| FY2016 | $5.6M | -4.1% |
As of FY2018 · SEC 10-K · Updated Feb 28, 2026